Positioning political selling, disclosed 2026-09-04
Options put/call open interest 0.09, read 2026-10-27
Ethical passes the values gate
Price137.67 USD
Fair value115.29
Ethical score88.2/100
RatingAVOID
Our investment reviews on this name
2026-10-11Read Accumulation130.98+5.1% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown130.98+5.1% to today Distribution gives way to Markdown after a 5% slide in 5 weeks
2026-08-26Read Distribution138.33-0.5% to today ✓Markup gives way to Distribution after a 195% rise in 8 weeks
2026-07-02Read Markup46.85+193.9% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
DuPont holds its Accumulation at $137.67. Consolidating, no directional conviction, held for 84 days.
As held on the ledger · 2026-10-27
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 84 days
Price at the screen
$137.67
Valuation
35.07 trailing · 16.31 forward price to earnings
Values screen
PASS· score 88.2
Beta
1.08
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
14.80%
Below 33%
Interest-bearing debt is just 14.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
2.00%
Below 33%
Cash held in interest-bearing accounts and securities is 2.0% of assets, under the one-third limit.
Pass
Receivables
7.53%
Below 49%
Money owed to the company is 7.5% of assets, under the 49% limit.
Pass
Revenue purity
1.43%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
DuPont clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 15%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DD's ethical verdict changes
Today DD passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $115.29 fair value estimate, weak competitive moat, 4.00% revenue growth.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. The price runs 11.6% above the base estimate.
Third-party analyst targets: 17 covering, consensus Buy. The average target sits +18% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
DuPont trades rich in a cyclical trap
Think of a chemical plant that keeps running even when demand drops off a cliff. DuPont sits in exactly that spot today, priced at a premium while its returns have all but flatlined.
We pass because the shares sit 13 percent above our fair value with a 17.9 times forward multiple, 4 percent revenue growth, zero profit margin and 1 percent ROE. Weak moat plus the cyclical nature of specialty chemicals turns the modest multiple into a warning sign rather than a bargain.
Peak-cycle earnings often look cheap on paper right before volumes and pricing reset lower, and that is the trap here despite the clean ethical screen. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Accumulation$130.45+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$130.45+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$130.45+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 43% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
2026-10-18Accumulation$130.45-0.4%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
2026-10-02Markdown · changed$130.98-5.3%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
2026-07-26Markup$135.29+188.8%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 188.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
2026-07-18Markup$46.85+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
2026-07-03Markup$46.85+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
